


Physician/Client Information		Patient Information	
Default Practice		Name: Default Patient	
Default MD		DOB: 00/00/0000	Age: 00
Default Address		Sex: M/F	
Default City, State, Zip		Phone #: (000) 000-0000	
Phone: (000) 000-0000		Ex MR#: 00000	
Fax: (000) 000-0000		Ex Acc #: 00-0000	
		Accession #: HS00-00000	
Collected: 00/00/0000	12:00 AM	Received: 00/00/0000	12:00 AM
		Reported: 00/00/0000	12:00 AM
		Report Status: Final	

DERMATOPATHOLOGY SERVICE

A. SKIN, LEFT SUPRA SCAPULAR AREA (EXCISION):

- EXCISION THROUGH THE DERMIS SHOWING RESIDUAL BASAL CELL CARCINOMA, COMPLETELY EXCISED (173.51).
- ADJACENT ATYPICAL LENTIGINOUS JUNCTIONAL MELANOCYtic PROLIFERATION, COMPLETELY EXCISED (238.2).
- CICATRIX AND CHANGES CONSISTENT WITH PREVIOUS BIOPSY SITE ARE PRESENT.



Microscopic Description and Comment:

A. Sections show skin excision through the dermis with a nodular dermal basaloid proliferation. There is adjacent orthokeratosis, pseudoepitheliomatous epidermal hyperplasia, superficial dermal scar and minimal superficial perivascular inflammation, with focal melanocytic hyperplasia and confluence of melanocytes, some of them enlarged, with clear nuclear chromatin. A Mart-1 immunohistochemical stain highlights the distribution of melanocytes. Margins are free of both basal cell carcinoma and atypical melanocytic proliferation.

Immunohistochemical Stains:

Stains performed at SEPA
Controls react appropriately
All tissue fixed in formalin and embedded in paraffin
Representative tissue identified in all sections examined
Mart-1: highlights the distribution of melanocytes.

Clinical Information Provided:

Nodular BCC, 173.51

Gross Description:

A. Specimen designated "left suprascapular area".
Specimen consists of a 3.5 x 2.0 x 0.5 cm oriented portion of skin. There is a score designating 12 o'clock.
Inking Code: Green-12-3-6 o'clock margin; Blue-remaining surgical margin
Section Code: A1-notched anterior tip; A2-A5-body; A6-posterior tip-specimen submitted in toto.

FDA Notice: Some of the tests utilized in the evaluation of this case may be of the type where the test was developed and the performance characteristics determined by SEPA Labs. The United States Food and Drug Administration has determined that these tests do not require FDA clearance or approval and these tests have not been submitted to the FDA for clearance or approval. These tests are used for clinical purposes only. These tests should not be regarded as investigational or for research only. SEPA Labs is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA-88) as qualified to perform high complexity laboratory testing.

CPT Codes: 88305, 88342

Electronically Signed 00/00/0000 00:00
Oana Radu M.D. (Dermatopathologist)